Since 1990’s scientists from Tomsk State University have been developing a glyoxal production technology. Glyoxal is a high-purity material possessing a broad spectrum of activity and low toxic level. The first Russian plant for glyoxal production which cost 150 million rubles was established in Toms in 2009. Russia became the eighth country in the world possessing glyoxal synthesis technology. The production of this substance in the RF has resulted in its cost reduction, which also makes glyoxal use economically sound. Glyoxal is used to produce explosive substances, propellants, medical items etc.
According to Knyazev, Tomsk State University (TSU), Tomsk Polytechnic University (TPU) and Siberian State Medical University participate in the project.
“Biodegradable polymers that can be used to produce surgical suture are among the most important medical materials based on glyoxal. The market of these materials is huge but equals zero in Russia since we lack industrial production. We have an idea to launch the first Russian production of glyoxal-based absorbable suture materials in Tomsk. We talk about monofilament suture material which surpasses other suture materials in fineness,” Knyazev said.
He explained that “higher education institutions will elaborate a complex technology to produce glyoxal-based absorbable sutures.”
“We have everything necessary to develop and introduce such technology in Tomsk. Synthesis chemists from TSU are studying ways of glycolic acid production from glyoxal. And synthesis and polymer chemists from TSU and TPU are engaged in the studies of polymer production from glycol acid as polymers constitute the basis for all materials. Synthesis chemists working at production enterprises will be able to make films and sutures from the polymers. Siberian State Medical University can perform clinical tests of the materials produced,” he said.
According to Knyazev, the project has already been launched, nowadays researchers “are receiving pilot samples of glycolic acid, polymers as well as developing devices that will allow to produce monofilament suture from the polymers.”
“We want to get all equipment ready within this year, launch all of them in 2013 and start production tests. Industrial-scale production may be launched in two-three years,” he said.
According to Knyazev, apart from the absorbable surgical suture researchers will also study the development technology of antiseptic sutures, sutures for different organs and so on. The project is planned to be financed through grants and federal targeted programs within the technological platform “Medicine of the Future”.
As the chairwoman Lyudmila Ogorodova said to journalists, the project may be financed from the Russian Foundation for Technological Development.
“This Foundation is the most attractive for us. It gives money without compensation, the payback period starts in five years when an enterprise has already got to its feet and launched production. Project participants could construct factory premises for the money granted by the Russian Foundation for Technological Development,” she said.
The technological platform “Medicine of the Future” has become the first officially established technological platform in Russia. It is aimed at the development of a segment of the RF medicine based on the complex of “breakthrough” technologies which determine the possibility of appearance of new high-tech product and service markets as well as of a rapid distribution of advance technologies in the medical and pharmaceutical industries.